Letermovir to Prevent CMV Reactivation After CAR T Cell Therapy
This study is looking at whether the drug Letermovir can prevent a common viral infection called cytomegalovirus (CMV) from becoming active in people receiving a specific type of cell therapy (CAR T cell therapy). You might be able to join if you are 18 or older, have good general health, are scheduled to receive AXI-CEL (a type of CAR T cell therapy), and have previously been exposed to CMV (meaning you have anti-CMV IgG antibodies). The main goal is to see how safe Letermovir is and what side effects it might cause over about one year. Researchers will also check if Letermovir helps prevent CMV from reactivating after your CAR T cell treatment.
- Study design
- This is a single-arm pilot study, meaning all 36 participants will receive the study drug. The phase of the study is not specified.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for safety and adverse events through study completion, which is an average of one year.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Single Arm Pilot Trial of Letermovir for CMV Prophy in CAR T Cell
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- George Chen, MD · PRINCIPAL_INVESTIGATOR · M.D. Anderson Cancer Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Safety and Adverse Events (AEs)Through study completion; an average of 1 year
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0